$1.57
3.09% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US2666051048
Symbol
DRRX
Sector
Industry

DURECT Corporation Stock price

$1.57
+0.20 14.60% 1M
+0.59 60.58% 6M
+0.98 166.10% YTD
-1.32 45.67% 1Y
-12.03 88.46% 3Y
-16.23 91.18% 5Y
-13.63 89.67% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.05 3.09%
ISIN
US2666051048
Symbol
DRRX
Sector
Industry

Key metrics

Market capitalization $48.73m
Enterprise Value $49.14m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.84
P/S ratio (TTM) P/S ratio 5.79
P/B ratio (TTM) P/B ratio 9.67
Revenue growth (TTM) Revenue growth -56.70%
Revenue (TTM) Revenue $8.41m
EBIT (operating result TTM) EBIT $-24.93m
Free Cash Flow (TTM) Free Cash Flow $-26.25m
Cash position $15.65m
EPS (TTM) EPS $-0.66
P/E forward negative
P/S forward 6.05
EV/Sales forward 6.10
Short interest 3.98%
Show more

Is DURECT Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

DURECT Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a DURECT Corporation forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a DURECT Corporation forecast:

Buy
50%
Hold
50%

Financial data from DURECT Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
8.41 8.41
57% 57%
100%
- Direct Costs 1.62 1.62
1% 1%
19%
6.92 6.92
61% 61%
82%
- Selling and Administrative Expenses 13 13
22% 22%
149%
- Research and Development Expense 19 19
47% 47%
228%
-25 -25
28% 28%
-296%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -25 -25
28% 28%
-296%
Net Profit -16 -16
56% 56%
-188%

In millions USD.

Don't miss a Thing! We will send you all news about DURECT Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DURECT Corporation Stock News

Neutral
PRNewsWire
3 days ago
CUPERTINO, Calif. , Sept. 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management's participation in the H.C.
Neutral
Seeking Alpha
25 days ago
DURECT Corporation (NASDAQ:DRRX ) Q2 2024 Results Conference Call August 13, 2024 4:30 PM ET Company Participants Tim Papp - CFO & Secretary Jim Brown - Co-Founder, CEO, President & Director WeiQi Lin - EVP, Research & Development and Principal Scientist Conference Call Participants François Brisebois - Oppenheimer Ed Arce - H.C. Wainwright Carl Byrnes - Northland Capital Markets Operator Ladie...
Neutral
PRNewsWire
25 days ago
-         FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis -         Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design -         Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 -         Webcast of Earnings Call Today, August 13th at 4:30 p.m. ET CUPERTINO, Calif.
More DURECT Corporation News

Company Profile

DURECT Corp. is a biopharmaceutical company. It engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Head office United States
CEO James Brown
Employees 58
Founded 1998
Website www.durect.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today